Assessment Licensing Information
The terms and conditions for licensing may be based on your
- organization’s status as not-for-profit or for-profit entity,
- research-funding status,
- intended use of the assessment,
- number of uses of the assessment, and
- desired term of use of the assessment.
Below you will find the process to obtain the non-negotiable non-exclusive license agreement.
Process for obtaining a license:
- Review the information within table to obtain the correct agreement.
- Complete the non-negotiable agreement where indicated and return the document to the OTM Contact.
- The OTM Contact will review and either
- begin the signature process, or
- contact you to obtain further information.
For questions regarding licensing each particular assessment, please email the managing OTM Contact indicated within each section below.
SNOT 16, 20 and 22
The Sino-Nasal Outcome Test Assessments (SNOT 16, SNOT 20 and SNOT 22) are patient-based rhinosinusitis outcome measures. Each SNOT Assessment contains questions concerning nasal blockage and a decreased sense of smell/taste, and each are a valid measure of rhinosinusitis health status and quality of life.
HEAR-QL (Child or Adolescent)
The Hearing Environments and Reflection on Quality of Life Questionnaires (HEAR-QL) are condition-specific quality-of-life questionnaires designed to (a) determine how a child or adolescent perceives the effects of hearing loss, and (b) aid the clinician in determining where intervention is warranted to improve the child’s or adolescent’s overall being.
The AD8 is an 8-question interview tool which distinguishes individuals with very mild dementia from those without dementia, regardless of etiology. The AD8 is based on intra-individual decline and has been demonstrated to be a valid and reliable screening tool for dementia.
The CDR is a 5-point scale used to characterize six domains of cognitive and functional performance applicable to Alzheimer Disease and related dementias: memory, orientation, judgment & problem solving, community affairs, home & hobbies, and personal care. The CDR provides descriptive anchors that guide the clinician in making appropriate ratings based on interview data and clinical judgment.
VarScan is a Java-based, platform-independent software tool that can detect variants in next-generation sequencing (NGS) data. It employs a robust statistical approach to call variants and is able to handle; germline variants, multi-sample variants, somatic mutations and somatic copy number alterations.
In continuous development at the one of the world’s leading genome centers and with an ever growing community of users, VarScan remains the premium variant caller in the market.
The summaries of terms for a Non-Exclusive Agreement are given below.
- Field: All uses, including research and commercial applications
- Territory: Worldwide
- Term: 3 years
- License Issue Fee: $5,000 (fully creditable towards the 1st year Annual License Fee)
- By the anniversary of Effective Date of each calendar year, Licensee shall provide WU with a written report specifying the number of Samples analyzed in the immediately preceding calendar year. Following receipt of such report from Licensee, WU shall issue an invoice to Licensee for applicable Annual License Fee.
- Annual License Fee:
Sample: means any unique pair of sequence/reference comparison where a sequence of nucleic acids is compared to a reference using Software or Derivative Works of Software. The reference may be a single sequence or collection of sequences.
Send the completed agreement to Scott Crick.
The Neonatal Eating Outcome (NEO) Assessment’s purpose is to assess age-appropriate oral motor and feeding skills in preterm infants prior to and at term equivalent age. This assessment attempts to gauge normal versus abnormal progression of feeding across differing postmenstrual ages (PMA), when lack of feeding success can be either a flag for abnormality or part of the normal process of maturation. It can be used with breast or bottle fed infants. Scoring of the NEO is based on the infant’s PMA at the time of assessment.
The full assessment is appropriate for infants who have initiated oral feeding (approximately 30-32 weeks PMA) through approximately 4-6 weeks post-term. An abbreviated form can be used for infants after 30 weeks PMA who are not yet orally feeding.
For information on obtaining the NEO Assessment, please contact Michael Muskus.
Your Disease Risk (YDR) is one of the longest running, publicly available health risk assessments on the Internet. Launched in early 2000 and continually updated to the present time, the site offers risk assessments for twelve different cancers plus five other important chronic diseases: heart disease, stroke, diabetes, COPD, and osteoporosis.
Developed by chronic disease epidemiologist, Dr. Graham Colditz, MD, DrPH, Associate Director for Prevention and Control at Siteman Cancer Center, the WashU YDR website is conservatively estimated to have reached over 4 million unique visitors since its launch. Over the past 12 months alone, it has hosted 250,000 unique visits, with 3.7 million page views.
Unique among most evidence-based assessments, YDR has a simple, straightforward interface. The assessment questions can be completed in a matter of minutes without any clinical data, and for each disease, the website offers both a visual and verbal risk estimate as well as personalized tips for prevention and lowering risk of disease. In published validation studies, the tool has been found to provide well-calibrated estimates of cancer risk and heart disease risk relative to the general population.
WashU offers a non-negotiable, non-exclusive license to assessment wording and logic as well as risk calculation and population prevalence (US) spreadsheets for YDR. Included under this license is documentation explaining the approach of the calculations and logic, as well as suggestions for potentially lowering your risk of certain diseases.
No software code or design elements are offered under this licensing mechanism. Also, if support services are required, they can be arranged under a separate agreement.
For additional information or for commercial use of YDR, please contact Michael Muskus.